YES - There is still time catch the Mosta-move coming to Inovio
As an update to my last chart on Inovio, (Which failed to reach the price targets within he time-frame suggested), I still am witness to extremely Bullish signals. Patience is certainly a key when investing in micro-cap bio-tech stocks.
Inovio maintains a robust pipeline, recently initiated a phase 1 DNA immunotherapy trial for breast, lung and pancreatic cancers, is actively seeking partnership(s) for their ongoing trials and will be presenting detailed analysis of their recently completed phase 2 cervical dysplasia trial in the near future.
My current chart (I believe) shows that "the market" has gained much interest and is awaiting the many possible catalysts that will develop over the next several months.
6 month price target - $12.40 -- 12 month price target $21.00
Inovio maintains a robust pipeline, recently initiated a phase 1 DNA immunotherapy trial for breast, lung and pancreatic cancers, is actively seeking partnership(s) for their ongoing trials and will be presenting detailed analysis of their recently completed phase 2 cervical dysplasia trial in the near future.
My current chart (I believe) shows that "the market" has gained much interest and is awaiting the many possible catalysts that will develop over the next several months.
6 month price target - $12.40 -- 12 month price target $21.00
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。